T

Telix Pharmaceuticals

Develops targeted radiation diagnostics and therapies

Theranostics Specialist

Full-TimeUpdated on 10/23/2026
No salary listed
Senior
Bachelor's, Master's
Remote in USA
RemoteCandidates must reside in Colorado, Utah, or California; must live within close proximity to a major airport.
Solution EngineeringImplementation & Technical Account Management

About the job

Requirements
  • A Bachelor of Science or Master of Science degree in a scientific discipline, preferably Radiology or a similar field, or equivalent experience.
  • Certification by the Nuclear Medicine Technology Certification Board or the American Registry of Radiologic Technologists is required.
  • Five years of experience with advanced oncologic PET/CT scanning and optimization.
  • Experience in radiopharmaceuticals is required; prostate cancer experience is preferred.
  • Thorough understanding of relevant policies guiding the pharmaceutical industry.
  • Experience or expertise in interpretation of scientific data, market research, and competitive intelligence tools.
  • Proficiency in Microsoft Office Suite.
  • A valid driver's license.
  • Must reside in Colorado, Utah, or California, live within close proximity to a major airport, and be willing to travel locally, regionally, and nationally up to 75%.
Responsibilities
  • Lead and oversee strategic onboarding of new imaging sites, integrating Telix radiopharmaceuticals into commercial and site workflows.
  • Develop and implement best practices for imaging-site optimization, including protocol standardization, scanner settings, and workflow efficiency improvements to ensure high-quality imaging outcomes.
  • Oversee and execute field activities for imaging sites in alignment with corporate strategy, supporting product launches and healthcare professional education.
  • Build and maintain high-level collaboration with Territory Account Managers within the assigned geography.
  • Contribute to the development and presentation of quarterly area business reviews.
  • Lead site-engagement strategies with imaging centers, nuclear medicine specialists, and key stakeholders to support patient access and product utilization.
  • Develop training materials, present product information, and ensure consistent knowledge dissemination to internal and external stakeholders.
  • Represent Telix at meetings and conferences and synthesize insights that inform company strategy.
  • Oversee competitive-intelligence gathering and market insights, keeping internal teams informed about industry trends, emerging technologies, and competitive landscapes.
  • Serve as a liaison among cross-functional teams and manage projects and initiatives to support efficient execution and measurable strategic impact.
  • Ensure compliance with pharmaceutical regulations, corporate policies, and ethical guidelines, addressing gaps in training or adherence.
Desired Qualifications
  • Prostate cancer experience.
  • A Radiology or similar scientific discipline.

About the company

Telix Pharmaceuticals develops and commercializes diagnostic and therapeutic products that use targeted radiation to diagnose and treat cancer and rare diseases. Its pipeline covers urologic oncology (prostate and kidney cancers), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. The treatments work by delivering targeted radiation to diseased tissues, enabling more precise decisions for treatment and allowing for personalized therapy. The company differentiates itself through a global, robust supply chain and a focus on integrating diagnostic and therapeutic options to address unmet medical needs, along with strong commitments to patient care, ethical practices, and environmental responsibility. Telix’s goal is to improve quality of life and outcomes for patients by providing targeted, clinically meaningful diagnostic and therapeutic solutions that support better treatment decisions and personalized care.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Get referred to Telix Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved Pixclara on September 13, 2026, opening Telix's first brain-cancer imaging market.
  • H1 2026 revenue reached $477 million, up 22%, with EBITDA rising 146%.
  • BiPASS enrolled 350 patients and Telix aligned with FDA on a U.S. NDA pathway.

What critics are saying

  • Telix still depends on FDA manufacturing acceptance for Zircaix resubmission in 2026.
  • The $2.35 billion ITM deal brings dilution, debt, and integration strain through 2027.
  • Novartis, with Lutathera and Pluvicto, attacks Telix in GEP-NETs and prostate therapy.

What makes Telix Pharmaceuticals unique

  • Telix sells both diagnostics and therapies across the same radiopharmaceutical platform.
  • Illuccix and Gozellix give Telix a commercial prostate imaging franchise in 24 countries.
  • ITM adds isotope manufacturing, distribution, and lutetium-177 supply across more than 65 countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Annual Performance Bonus
  • Equity-Based Incentive Program
  • Paid Vacation
  • Paid Wellness Days
  • Hybrid Work Options
  • Remote Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

16%

2 year growth

1%
Capital Brief
Oct 21st, 2026
SpaceX Q3 earnings smash expectations as AI revenue soars.

SpaceX Q3 earnings smash expectations as AI revenue soars. Stocks Slide Telix Pharmaceuticals shares slump despite Q3 revenue growth. 6:20pm today The news: Shares in Telix Pharmaceuticals tumbled in morning trade despite the global biopharmaceutical company reporting a 19% year-on-year increase in third quarter group revenue to USD245 million ($349 million). Shares slumped 7.3% to $14.60 at 11:54am AEDT. The context: The company saidthe revenue growth was supported by its precision medicine division, which recorded a 30% year-on-year jump to USD201 million. This was primarily driven by sustained demand for its flagship imaging products Gozellix and Illuccix. The strong performance follows the FDA approval of its brain cancer (glioma) imaging agent, Pixclara in the US earlier in September, with first commercial sets of patients successfully dosed in early October. Telix expects to generate total full-year revenue and other income of over USD1 billion, tracking toward the upper end of its core product guidance of between USD950 million and USD970 million. The source: ASX Get Letter of Intent in your inbox. The jobs marketplace is hoping to reel in $700m by selling non-core parts of its investment portfolio. At current valuations, that may prove a hard sell. Hugo Mathers · 9:31pm today Two of Australia's established data centre companies insist there is still strong support for proven players in their industry despite Firmus' pulled IPO. Brandon How · 10:41pm yesterday Private equity is finding treasure in the ASX's unglamorous businesses, with a flurry of takeover deals on Monday for bins, pipes and car fleets. Hugo Mathers · 19 October 2026

Daily Dispatch
Oct 20th, 2026
Philadelphia cyclotron to give Telix a dedicated source of rare alpha isotope.

Philadelphia cyclotron to give Telix a dedicated source of rare alpha isotope. Telix has partnered with a new Franco-Belgian venture to produce astatine-211 in the United States. The isotope is scarce but is being studied closely as a new way to deliver radiation straight to cancer cells. The collaboration is with Ekalia, a joint venture between Belgian cyclotron maker IBA and French nuclear group Framatome. The first of IBA's alpha-beam cyclotrons will be installed and run at Telix's RLS Radiopharmacies site in Trevose, near Philadelphia. Astatine-211 is an alpha-emitting radioisotope under investigation for targeted alpha therapy. In this approach, a drug carries a radioactive payload directly to a tumour. The partners describe the isotope as promising for new cancer treatments, but say limited production capacity has held back wider use. Their answer is a network of production sites close to the clinical centres that need the isotope. Ekalia chief executive Bruno Scutnaire said the technology was designed to put production where it is needed. "IBA's specialised alpha-beam cyclotron technology is designed to enable reliable astatine-211 production at the point of need. Building on our work with Framatome in Europe, Telix's U.S. infrastructure enables us to move faster towards establishing our first U.S. production unit, while laying the foundations for Ekalia's broader development in the country." The deal brings the IBA-Framatome partnership, set up in Europe to produce astatine-211 at industrial scale, into the US. Each company brings something different. IBA supplies the cyclotron technology and Framatome its nuclear and isotope production expertise. Telix contributes its US radiopharmacy network and "last-mile" distribution, along with its clinical portfolio and drug development capability.

Yahoo Finance
Oct 19th, 2026
Telix and Ekalia team up to produce astatine-211 in the US for cancer therapy

Telix Pharmaceuticals and Ekalia, a joint venture between IBA and Framatome, will collaborate on US production of astatine-211, an alpha-emitting isotope being studied for targeted alpha therapy. They announced the deal on October 19, 2026. The first IBA alpha-beam cyclotron will be installed at Telix's RLS Radiopharmacies site in Trevose, near Philadelphia. The parties may add more RLS sites as demand grows. The deal gives Telix long-term, priority access to the isotope for its alpha therapy pipeline, including TLX102-Tx, a candidate for glioblastoma and leptomeningeal disease. It will also supply third-party academic and industry programmes. Astatine-211 is promising, but limited production capacity has held back wider use.

Yahoo Finance
Oct 18th, 2026
Three Australian growth stocks with insider backing: PDI Gold, Telix and Codan

Simply Wall St has picked three Australian growth stocks with high insider ownership: PDI Gold, Telix Pharmaceuticals, and Codan. The screen favours fast growers that can handle higher costs as US inflation keeps interest rate risks in focus. PDI Gold (market cap A$4.3 billion) runs the Kiniéro Gold Mine in Guinea. Its reliance on oxide ore could lift costs and squeeze margins once that phase ends. Telix Pharmaceuticals (A$5.3 billion) develops radiopharmaceutical imaging agents and cancer therapies. Its imaging products brought in $803.8 million (USD) in the 2025 financial year, and growth hinges on its late-stage pipeline. Codan (A$11.4 billion) makes radio communications systems and metal detectors. Rising defence spending and demand for unmanned systems are expanding its order book.

Anderson Publishing, Ltd.
Oct 14th, 2026
Telix to present 20 abstracts at EANM 2026 Congress.

Telix to present 20 abstracts at EANM 2026 Congress. October 14, 2026 · News Release Telix has announced that it will be presenting 20 company-related abstracts at the forthcoming 39th Annual Congress of the European Association of Nuclear Medicine (EANM) scheduled for October 17-21, 2026, in Vienna, Austria. Dr. David N. Cade, Chief Medical Officer of Telix, emphasized that the company's robust presence at the event showcases the extensive development of its pipeline, which includes important therapeutic studies, precision diagnostics, and advanced technologies. He noted that the inclusion of 12 abstracts in top-rated oral presentations is a significant acknowledgment of the quality and clinical relevance of Telix's research. A symposium focusing on the future of theranostics in urologic oncology is also planned. Key presentations will feature pivotal trials such as the Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma, the Phase 3 LUTEON trial of TLX250-Tx in clear cell renal cell carcinoma (ccRCC), and interim results from the PTherpan-Lu trial of TLX597-Tx in metastatic androgen pathway modulation-resistant prostate cancer (mAPMR). The event will also highlight topline Phase 3 data for TLX591-Px (Illuccix) PET imaging in prostate cancer among Chinese men, as well as real-world applications of TLX250-Px (Zircaix) in ccRCC. Additionally, Telix will sponsor the EANM Sanjiv Sam Gambhir Young Investigator Award to honor the legacy of the esteemed educator. Attendees can visit booth #527 to learn more about collaboration opportunities involving Illuccix(R), the PSMA-PET imaging agent, along with contributions from Telix's theranostic pipeline and innovative medical technologies, including the SENSEI(R) miniature drop-in gamma probe and QDOSE(R) dosimetry software. Sponsored symposium details. Title: The future doesn't wait: The next era of theranostics in urologic oncology. Date & Time: 18-Oct-26, 13:15 - 14:45 Location: Hall F2, Austria Center Vienna Chair: J. Calais, Gustave Roussy, IGR and Université Paris-Saclay, Paris, France * The theranostic revolution * The evolving role of PSMA-PET in prostate cancer * Next-generation PSMA therapeutics: Overcoming today's challenges * Panel discussion * Extending prostate cancer theranostic success to broader GU diseases Selected oral presentations. * ELEGANCE: Prospective pilot study assessing imaging performance of TLX250-Px in patients with hepatocellular carcinoma, biliary tract cancer or gastro-enteropancreatic neuroendocrine neoplasms. * * Date and Time: 18-Oct-26, 08:00 - 09:30 * Presenter: Clement Bailly * HIMIKO: TLX591-Px PET/CT in hepatocellular carcinoma. * * Date and Time: 18-Oct-26, 08:00 - 09:30 * Presenter: Rachel Bardy * Exploring carbonic anhydrase IX as a diagnostic imaging target using TLX250-Px in Von Hippel-Lindau Disease. * * Date and Time: 18-Oct-26, 15:00 - 16:30 * Presenter: Fabrizia Gelardi * LUTEON: Phase 3 study assessing safety and efficacy of TLX250-Tx in advanced ccRCC. * * Date and Time: 18-Oct-26, 15:00 - 16:30 * Presenter: Ghoufrane Tlili * Building the traceability backbone for radiopharmaceutical therapy: First results from the PDIB Secondary Standards Laboratory Network. * * Date and Time: 19-Oct-26, 08:00 - 09:30 * Presenter: Steven Graves With the exception of Illuccix, all products mentioned are investigational and have not received marketing authorization in any jurisdiction. More in theranostics. October 15, 2026 October 6, 2026